Cancer-Associated Thrombosis and CVAD-Related VTE: A Comprehensive Clinical Guideline

Evidence-based guideline for risk assessment, prophylaxis, diagnosis, and treatment of venous thromboembolism in cancer patients, including catheter-related thrombosis.

5 articles • Updated Mar 2026

Cancer-Associated Thrombosis — Part 5: CVAD-Related Thrombosis Management and Patient Education

Comprehensive management of central venous access device-related thrombosis including diagnosis, treatment, catheter management decisions, upper extremity DVT, patient education, monitoring, and follow-up.

guidelines•Mar 2026•guidelines

Cancer-Associated Thrombosis — Part 4: Special Situations and Populations

Management of cancer-associated VTE in special populations including brain tumors, thrombocytopenia, renal impairment, GI/GU cancers, recurrent VTE on anticoagulation, incidental and subsegmental PE, and IVC filter indications.

guidelines•Mar 2026•guidelines

Cancer-Associated Thrombosis — Part 3: Treatment of Established Cancer-Associated VTE

Complete treatment protocols for cancer-associated VTE including LMWH dosing, DOAC regimens (rivaroxaban, edoxaban, apixaban), warfarin considerations, duration of anticoagulation, and landmark trial data from SELECT-D, HOKUSAI-VTE Cancer, ADAM-VTE, and CARAVAGGIO.

guidelines•Mar 2026•guidelines

Cancer-Associated Thrombosis — Part 2: VTE Prophylaxis in Cancer Patients

Evidence-based recommendations for VTE prophylaxis in ambulatory, hospitalized, and surgical cancer patients, including CVAD-related thrombosis prevention, with complete dosing tables and key trial data.

guidelines•Mar 2026•guidelines

Cancer-Associated Thrombosis — Part 1: Pathophysiology and Risk Assessment

Pathophysiology of cancer-associated thrombosis, Virchow's triad in malignancy, and validated VTE risk assessment models including the Khorana score, Vienna CATS score, PROTECHT score, and ONKOTEV score with complete scoring tables.

guidelines•Mar 2026•guidelines